Bitter Pills:Medicines & The Third World Poor | Page 254
38
Statement of Hon. Michael D. Barnes, a Representative in Congress from the State of Maryland,
lixport of Hazardous Products, hearings before the Sub- Committee on International Economic
Policy and Trade of the Committee on Foreign Affairs, House of Representatives, Ninetysixth Congress, June 5,12, and September 9 1980, US Government Printing Office, Washington,
1980, p.3.
39
In Britain, Member of Parliament Jack Ashley was told that detailed breakdowns of drug
exports were not available and could only be collected at disproportionate cost.
40
Ralph Cox, Department of Health and Social Security, personal communication, 29 October,
1981.
41
Lord Wells-Pestell, ParliamentaryUnder-SecretaryofState, Department of Health and Social
Security, House of Lords, Hansard, 21 February 1979.
42
Hansard, 30 January 1979, column 1433.
43
"The Penang Declaration on the Export of Hazardous Substances and Facilities", signed by
participants at the First International Consumer Testing Course in Penang, 29 October - 25
November 1980, para.l(a).
44
Ibid, para.l(b)(i).
45
Barnes, op.cit.
46
"Report to the President on the Review of US Hazardous Substances Export Policy and cover
letter to US Trade Representative Brock from Secretaries Haigand Baldridge", 10 May 1982,
US Export Weekly- Memorandum from S. Jacob Scherr, Natural Resources DefenseCouncil,
Inc., 24 June 1982.
47
Roland Moyle, DHSS, Replies to Parliamentary Questions, Hansard, 12 and 19 March 1979.
48
-
49
WHO, Quality Control of Drugs, A. Good Practices in Manufacture; B. Certification scheme
for products moving in international commerce, Geneva, 1977.
50
WHO, (A35/7) 1 April 1982, op.cit., pp.3-4.
51
As (49) and (50).
LetterfromKennethClarke,HealthMinister,toSydneyChapmanM.P.,6April 1982.
Cox, personal communication, 29 October 1981, op.cit.
52
As (49).
53
Cox, op.cit.,: "The United Kingdom for its part would certainly respond sympathetically and
constructively to any approach from a reGulatory authority which sought additonal help."
54
Hakan Mandahl, Assistant Director, Department of Drugs, National Board of Health and
Welfare, Uppsala, Sweden, in interview with the author, 15 April 1982.
55
"WHO Europe meeting turns down drug evaluation scheme," SCRIP No. 628,23 September
1981, p.2.
56
Dr. Dukes, WHO (Europe) Regional Officer for Pharmaceuticals, at international drug
regulation session of the US Food and Drug Law Institute, Washington, quoted in SCRIP
No. 697, 31 May 1982, p.10.
57
SCRIP No. 628, op.cit.
58
Review in SCRIP No. 684, 14 April 1982, p.5. "Drug Problems in Nordic countries in t